51 results
Page 2 of 3
40-F
EX-99.1
2g8t4
17 Mar 21
Annual report (Canada)
12:00am
6-K
EX-99.1
fkmugq 16f2rvla5
11 Feb 21
FSD Pharma Inc. 6-K
9:13am
SUPPL
7ht85fpvm8pocy0ta1v
11 Feb 21
Supplemental materials (foreign)
8:32am
6-K
EX-99.1
cdn22kwgf6t5es i6m9x
29 Jan 21
Material Change Report
6:00am
6-K
EX-99.1
9pmnmw
26 Jan 21
FSD Pharma Inc. 6-K
9:20pm
6-K
EX-99.1
p50ps2 14
22 Jan 21
FSD Pharma Inc. 6-K
4:56pm
6-K
EX-99.1
7m4fum 0opi4ogv6rk3v
15 Dec 20
FSD Pharma Inc. 6-K
10:35am
6-K
EX-99.1
zowv3x
16 Nov 20
Management’s Discussion and Analysis of Financial Condition and Results of
10:59am
6-K
EX-99.3
jac2pzl542s ax6rl8
16 Nov 20
Management’s Discussion and Analysis of Financial Condition and Results of
10:59am
SUPPL
9dn8jgo
16 Oct 20
Supplemental materials (foreign)
5:19pm
6-K
EX-99.1
vgakisg7otcv
14 Oct 20
Material Change Report
8:26pm
6-K
EX-99.1
qtfwki jbwgmuow
29 Sep 20
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
10:35am
6-K
EX-99.1
p4z36fm
1 Sep 20
FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients with COVID-19
12:00am
6-K
EX-99.1
hk4vhoz82q 7f86d
11 Aug 20
Management’s Discussion and Analysis of Financial Condition and Results of
12:00am
SUPPL
7h6bv
31 Jul 20
Supplemental materials (foreign)
9:43pm
SUPPL
2p9fabs
13 Jul 20
Supplemental materials (foreign)
12:00am
6-K
EX-99.1
e46hda9
22 Jun 20
FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA
11:40am
F-10/A
fs04 rkbfd9ol3kii4yf
16 Jun 20
Registration of securities (Canada) (amended)
9:20pm
6-K
EX-99.1
8q9m6t2a309vjv1kz3
16 Jun 20
Material Change Report
12:00am
6-K
EX-99.1
262 47g30
3 Jun 20
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
10:41am